Long-acting CERA significantly increases circulating CD34-positive cells compared with short-acting epoetin-beta in patients undergoing hemodialysis

Long-acting CERA significantly increases circulating CD34-positive cells compared with short-acting epoetin-beta in patients undergoing hemodialysis - Effects of CERA on circulating EPC levels

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021659

Enrollment

Registered

2016-03-29

Start date

2013-05-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with chronic renal failure undergoing hemodialysis

Interventions

Patients were randomly assigned to CERA treatment for 6 months. Patients were randomly assigned to Epoetin-beta treatment for 6 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients whose hemoglobin concentration are within 11+/- 1.0 g/dl during the last 3 months.

Exclusion criteria

Exclusion criteria: Exclusion criteria were concomitant chronic inflammatory diseases or clinically manifest acute infections, malignant diseases, manifest or occult bleeding conditions, and recent cardiovascular events (at least 6 months).

Design outcomes

Primary

Measure	Time frame
Effects of CERA and epoetin-beta on numbers of circulating endothelial progenitor cells	—

Countries

Japan

Contacts

Public ContactSumi Hidaka

Shonan Kamakura General Hospital Kidney Disease and Transplant Center

s_hidaka@shonankamakura.or.jp+81-467-46-1717

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026